Acute Coronary Syndrome: Market Research Report

April 2010 | 752 pages | ID: ACCB9776A76EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Inverness Medical Innovations, Inc., Merck & Co., Inc., Medicure Inc., Novartis AG, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Schering-Plough Corp., Siemens Healthcare Diagnostics, Inc., Takeda Pharmaceutical Company Limited, and The Medicines Company.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Acute Coronary Syndrome – A Primer

Table 1. World Recent Past, Current & Future Analysis for Acute Coronary Syndrome Therapeutics Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Global ACS Drugs Market Scenario

Table 2. Leading ACS Drugs with Global Sales Revenues (in US$ billion) for the Year 2008 (includes corresponding Graph/Chart)

Table 3. Select Leading Myocardial Infarction Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart)

Table 4. Select Leading Coronary Artery Disease/ Atherosclerosis Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart)

Table 5. Select Leading Angina Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart)

Table 6. Estimated Number of Products Available for Select ACS Indications (includes corresponding Graph/Chart)

Key Market Drivers and Constraints
Antithrombotics – The Driving Force in Future
Combination Products
Drug Delivery Technologies
Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs
Patent Expiry of Best Selling Products: A Key Concern for the Industry
List of Leading Cardiovascular Drugs on the Verse of Patent Expiry
Lack of Product Differentiation
Fewer Product Introductions
Market Characteristics
United States and Europe – Far Ahead and Far More Powerful
Anticoagulants – Remarkable Drug Development Potential
Anticoagulants to Lose ACS Indications to Antiplatelets
Novel Anticoagulants to Drive Atrial Fibrillation Drug Market
Protein Therapy Research Promises Cardiovascular Disease Treatment
Future Directions: Shape Of Things To Come

Table 7. Estimated Number of Pipeline Products by Select ACS Indication (includes corresponding Graph/Chart)

Table 8. Estimated Number of Candidates in Development Phase by Select ACS Indication (includes corresponding Graph/Chart)

List of Cardiovascular (including ACS) Pipeline Products in Phase III Development (as of March 2007)
List of Cardiovascular (including ACS) Pipeline Products in Phase II Development (as of March 2007)
List of Cardiovascular (including ACS) Pipeline Products in Phase I Development (as of March 2007)
List of Cardiovascular (including ACS) Pipeline Products in Pre-clinical Development (as of March 2007)
Pharmaceutical Industry: A Review of the Current Scenario
Industry Framework
Consolidation Gets Underway
Patent Expiries Giving Way to Generic Drugs
Developing Countries Hold the Key to Future Growth

Table 9. World Pharmaceutical Industry (2007): BRIC Nations (Brazil, Russia, India and China), & United States Ranked by Percentage Growth (includes corresponding Graph/Chart)

Impact of the Recession: An Unequivocal Review

2.DISEASE OVERVIEW

Definition And Pathophysiology
Cardiac Circulation and Conduction
Acute Coronary Syndrome – A Definition
Underlying Cause of ACS
Unstable Angina
Causes and Symptoms
Treatment Options
Myocardial Infarction (MI)
Non-ST-Segment Elevated Myocardial Infarction (NSTEMI)
ST-Segment Elevated Myocardial Infarction (STEMI)
Chain Reaction After an Event of MI
Action Plan after an Event of MI
Causes and Symptoms
Drug Treatment Options
Epidemiology
Cardiovascular Diseases

Table 10. Region-Wise Incidence and Prevalence of Cardiovascular Diseases in 2006 (includes corresponding Graph/Chart)

Factors Responsible for Coronary Diseases
Uncontrollable Risk Factors
Ageing Global Population

Table 11. World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart)

Heredity
Gender
Diabetes
Controllable Risk Factors
High Blood Cholesterol
HDL Cholesterol
HDL Cholesterol Levels and Potential Risk of Cardiovascular Disease
LDL Cholesterol
LDL Cholesterol Levels and Potential Risk of Cardiovascular Disease
Triglyceride Levels
Triglyceride Level and Potential Risk of Cardiovascular Disease
Smoking
Changing Habits and Lifestyle
High Blood Pressure
Causative Risk Factors
Stress and Anger
Obesity
Disease Investigation And Diagnosis
ECG
Exercise ECG (ECG Stress Testing)
Test Procedure and Precautions
Blood Tests (for the Presence of Cardiac Biomarkers)
Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations
C-Reactive Protein
Necessity of a Cardiac Marker Assay Test
How it Works?
Need for Early Detection Markers
Strong Demand for Risk Assessment Markers
Invasive Imaging Tests
Coronary Angiography (or Cardiac Angiography)
Test Procedure and Results
Intravascular Ultrasound (IVUS)
Test Procedure and Results
Medication Strategies
Anti-ischemic Agents
Nitrates
Description on Some of the Nitrate Drugs for Acute Coronary Syndrome
Usage of Nitrates in ACS Indications
Unstable Angina (UA)
Acute Myocardial Infarction (AMI)
( Blockers
List of Indications for Select Beta-blocker Drugs
Calcium Channel Blockers
List of Indications for Select Calcium Channel Blockers
ACE and ACE II Inhibitor Drugs
Angiotensin Converting Enzyme (ACE) Inhibitors
List of Different Types of ACE Inhibitors and Products
Angiotensin II Receptor Antagonists (ACE II or sartans)
List of Different Types of Angiotensin II Receptor Antagonists and Products
Cholesterol Reducing Drugs
Statins Lead the Way
Emerging Leaders

Table 12. Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes corresponding Graph/Chart)

Lack of Product Differentiation Mars Prospects
Zocor – The First Statin to Switch to OTC
Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond
Anticoagulants
Anticoagulant Drug Classes
Oral Anticoagulants
Warfarin
Coumadin
Injectable Anticoagulants
Heparin
Unfractionated Heparin
Low Molecular Weight Heparin (LMWH)
A Snapshot of Available Anticoagulant Therapies
Antiplatelet Agents
List of Indications for Select Antiplatelet Drugs
Thrombolytics
Key Indications Relating to ACS
Others
Aspirin
Oxygen Supply
Pain Reliving Agents
Revascularization Procedures
Invasive Treatments
Bypass Surgery
Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty)
Coronary Stents
Drug Eluting Stents Steal the Show
Applications of Coronary Stents
Key Stents Delivery Platforms by Select Company
Coronary Stents – Leading Players

Table 13. Leading Players in the Global Coronary Stents Market (2006-2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, Medtronic, and Others (includes corresponding Graph/Chart)

Bare Metal Stents – Leading Players

Table 14. Leading Players in the Global Bare Metal Stents Market (2006-2008) – Percentage Breakdown by Revenues for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart)

Drug-Eluting Stents – Leading Players

Table 15. Leading Players in the Global Drug-Eluting Stents Market (2006-2008) – Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, and Medtronic (includes corresponding Graph/Chart)

Cell Transplantation – An Emerging Procedure For Chronic Heart Ailments

3.REGIONAL MARKET OVERVIEW

The United States
Cardiovascular Diseases in the US: A Review

Table 16. The US Disease Statistics for Coronary Heart Disease (CHD) & Myocardial Infarction (MI) (includes corresponding Graph/Chart)

AHA Statistics for Coronary Heart Disease

Table 17. The US Prevalence of Coronary Heart Disease (CHD) as a Percentage of Total Population by Age group and Sex, in 2005-06 (includes corresponding Graph/Chart)

Table 18. The US Prevalence of Stroke as a Percentage of Total Population by Age group and Sex, in 2005-06 (includes corresponding Graph/Chart)

Statistics from NCHS and NHLBI on ‘Death Due to Cardiovascular Diseases’

Table 19. Mortality Rate in the US for the Year 2006 by Cardiovascular Diseases -Percentage Breakdown of Deaths from Coronary Heart Disease, Stroke, High Blood Pressure, Heart Failure, Diseases of the Arteries, and Others (includes corresponding Graph/Chart)

Table 20. Mortality Rate in the US Males for the Year 2005 by Ailment - Heart Diseases, Cancer, Accidents, Chronic Lower Respiratory Diseases, and Diabetes (includes corresponding Graph/Chart)

Table 21. Mortality Rate in the US Females for the Year 2005 by Ailment - Heart Diseases, Cancer, Chronic Lower Respiratory Diseases, Alzheimer’s, and Accidents (includes corresponding Graph/Chart)

Fall in Number of Deaths due to Heart Diseases & Strokes
Senior Citizens at High Risk for Heart Failure
Baby Boomers Boost Coronary Stent Market
Generics Trigger Price war

Table 22. US Cardiovascular Drugs Market – Total Prescriptions by Drug Class (in Thousands) for the Years 2008 and 2009 (includes corresponding Graph/Chart)

Table 23. Select Leading Myocardial Infarction Drugs in the US: Value Sales in US$ Million for the Years 2007 and 2008 (includes corresponding Graph/Chart)

Table 24. Select Leading Coronary Artery Disease/ Atherosclerosis Drugs in the US: Value Sales in US$ Million for the Years 2007 and 2008 (includes corresponding Graph/Chart)

Table 25. Select Leading Angina Drugs in the US: Value Sales in US$ Million for the Years 2007 and 2008 (includes corresponding Graph/Chart)

Antihyperlipidemics

Table 26. US Cardiovascular Drugs Market for Statins (HMG CoA-Reductase Inhibitors) – Type of Statin Ranked by Value Sales in US$ Million for the Year 2007 (includes corresponding Graph/Chart)

Table 27. US Antihyperlipidemic Drugs Market (2007): Percentage Share Breakdown of Total Prescriptions by Leading Drugs (includes corresponding Graph/Chart)

Anticoagulants and Antiplatelets

Table 28. US Anticoagulant Drugs Market (2007): Percentage Share Breakdown of Total Prescriptions by Leading Product (includes corresponding Graph/Chart)

Drug Development Pipeline
US Pharmaceutical Sector Scenario

Table 29. US Pharmaceutical Market (2008) – Leading Pharmaceutical Companies Ranked by Value Sales in US$ Million (includes corresponding Graph/Chart)

Table 30. US Pharmaceutical Market (2007) - Leading Pharmaceutical Products Ranked by Value Sales in US$ Million (includes corresponding Graph/Chart)

Table 31. US Pharmaceuticals Market (2008) - Leading Therapeutic Class Ranked by Value Sales in US$ Million (includes corresponding Graph/Chart)

Table 32. US Cardiovascular Drugs Market (2008) - Leading Companies Ranked by Cardiovascular Drug Sales in US$ Million (includes corresponding Graph/Chart)

Canada
Leading Drugs in Canada

Table 33. Leading Prescription Drugs in Canada (2006 & 2007) - Number of Dispensed Prescriptions in Million Scripts for Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa (includes corresponding Graph/Chart)

Europe
European Cardiovascular Diseases Fact Sheet
Cardiovascular Disease – Risk Factor Profile
The Cardiovascular Disease Cost Burden
Mortality by Heart Attack Declines
EU to Face Health Care Expenditure Challenge Head-on

4.PRODUCT LAUNCHES/APPROVALS/ DEVELOPMENTS

FDA Approves Prasugrel
Efient® (Prasugrel) Obtains Approval by European Commission
The Medicines Company Obtains Approval for Angiox® by European Union
CV Therapeutics Obtains FDA Approval for New Indication for Ranexa
BMS and Pfizer Announce APPRAISE-1 Results for Apixaban
Scottish Medicines Consortium Issues Approval for Various Drugs
Schweizerhall Holding AG/Cimex AG to Launch Plavix® (Clopidogrel) Generic
Response Bags FDA Clearance for RAMP® NT-proBNP Test
PLAVIX® Receives FDA Nod
Sanofi-aventis Wins FDA Approval to Use Lovenox in STEMI Patients
GlaxoSmithKline Receives FDA Approval for Arixtra Injection
GlaxoSmithKline Wins EMEA Approval for Arixtra
GlaxoSmithKline Wins MHLW Approval for Arixtra
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US
GlaxoSmithKline Introduces Coreg CR™

5.RECENT INDUSTRY ACTIVITY

Pfizer Acquires Wyeth
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick
Arca biopharma Merges with Nuvelo
Merck Merges Business with Schering-Plough
Portola Pharmaceuticals Enters into Partnership with Novartis
Richter-Helm Signs Agreement with Athera Biotechnologies
Daiichi Sankyo Sets Up Subsidiary
Zydus Cadila Joins Forces with Eli Lilly for Cardiovascular Drug Research
AtCor Medical Enters into Contract with Pharmaceutical Company
Takeda Acquires Millenium Pharmaceuticals
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business
Shionogi Acquires Sciele Pharma
GlaxoSmithKline Acquires Reliant Pharmaceuticals
Recordati Acquires Yeni Ilac
China Sky One to Take Over Heilongjiang Tianlong Pharmaceutical
King Pharmaceuticals to Acquire Alpharma
GlaxoSmithKline to Acquire Bristol-Myers Squibb Pakistan
Meda Signs Deal to Take Over Roche Pharmaceutical Products
Belupo and Farmavita Announce Merger
Iroko Acquires Aggrastat’s Rights from Merck
Biological E Collaborates with Choncept and Heparinex
Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb
BMS and KAI Sign Pact to Develop, Commercialize Cardiovascular Drug
CV Therapeutics and Menarini Group Sign Deal for Ranexa
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement
Daiichi Sankyo Submits Application for Antihypertensive Drug Approval
Daiichi Sankyo Establishes Subsidiary in Ireland
PAION Announces Acquisition of Global Rights to Trigen’s flovagatran
Cardiovascular Systems Merges with Replidyne
Amic Recieves Non-Exclusive License from Roche Diagnostics
Iroko Pharmaceuticals Wins Rights to Aggrastat®
Sepracor Acquires Oryx Pharmaceuticals
GSK Acquires Reliant Pharmaceuticals
Schering-Plough Takes Over Organon BioSciences
Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal
Merck Acquires NovaCardia
Bristol-Myers and Pfizer Ink Development and Commercialization Agreements
Inverness Acquires Biosite
Siemens Acquires Diagnostic Division of Bayer Healthcare
Siemens Announces Acquisition of Dade Behring
Inverness Acquires Cholestech
Sanofi-aventis Acquires Rights for Panaldine from Daiichi Sankyo
Corautus Genetics and VIA Pharmaceuticals Sign Merger Agreement
Alchemia Inks Marketing Alliance with Dr. Reddy’s for Heparin
Recordati- Berlin Chemie Expand Licensing Agreement

6.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories Inc. (US)
AstraZeneca (UK)
Bayer AG (Germany)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (US)
Daiichi Sankyo Company Limited (Japan)
Dr. Reddy's Laboratories Ltd. (India)
Eli Lilly and Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline plc (UK)
Inverness Medical Innovations, Inc. (US)
Merck & Co., Inc. (US)
Medicure Inc. (Canada)
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Wyeth (US)
Sanofi-Aventis SA (France)
Schering-Plough Corp. (US)
Siemens Healthcare Diagnostics, Inc. (US)
Takeda Pharmaceutical Company Limited (Japan)
The Medicines Company (US)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 60 (including Divisions/Subsidiaries - 73)
Region/CountryPlayers
The United States34
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Latin America